A Clomiphene Citrate and Letrozol Varsus Tamoxifen and Letrozole as an Infertility Treatment in Women with Polycystic Ovary Syndrome

Athar, Rasekhjahromi; Maalhagh, Mehrnoosh; Hosseinpoor, Masoumeh; Hooshmand, Farhang; Alavi, Fatemeh

doi:10.3923/pjbs.2015.300.303

Cited by 2 publications

(2 citation statements)

References 25 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, Rasekhjahromi Atharn et al on 2015 found that combination of Clomid and Letrozole for induction of ovulation in PCOS patients has good ovulation rate 20% [21] . Also, Abu Hashim et al reported that 30% of their PCOS patients were resistant to clomiphene, but Letrozole induced an ovulation rate in those CC-resistant patients (64.9%) with pregnancy rate of 14.7% [11] .…”

Section: Discussionmentioning

confidence: 99%

“…But Masomeh et al (2013) reported that there was 23.8% abortion rate with combined CC and Letrozole therapy [15] . Also, Rasekhjahromi Athar et al (2015) reported miscarriage rate of about 2.4 % with CC plus Letrozole in PCOS infertile females [21] . Speroff and Fritz reported that the frequency of abortion following gonadotropins in their clomiphene-resistant patients was 20%-25%, which is more than that in the general population (15%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combined Letrozole and Clomiphene versus Letrozole with low dose gonadotropin protocol for ovulation induction in infertile clomiphene-resistant women with polycystic ovary syndrome: Comparative study

Harira

2018

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Combined Letrozole and Clomiphene versus Letrozole with low dose gonadotropin protocol for ovulation induction in infertile clomiphene-resistant women with polycystic ovary syndrome: Comparative study

Harira

2018

Evidence Based Women's Health Journal

View full text Add to dashboard Cite

show abstract

Safety of clomiphene citrate: a literature review

et al. 2017

View full text Add to dashboard Cite

Clomiphene citrate (CC) is a nonsteroidal compound and induces ovulation indirectly. The wide usage of the CC raises a question; is it safe or not? In the light of this question, this review aimed to highlight all researches and insights into the association between the use of CC and risk of genotoxicity, cytotoxicity, embryotoxicity, teratogenicity and risk of different cancer types. We conducted a MEDLINE/PubMed, Scopus, Web of Science, Google Scholar search. After a careful screening process of all authors, 32 of these articles were considered as appropriate, and reviewed. Our evaluations showed that CC has genotoxic, cytotoxic, embryotoxic and teratogenic properties. There is no association between the use of CC and risk of ovarian, breast, uterine, cervix, endometrium, lung, colorectal cancer, and lymphoma. However, risk increased especially after 6 cycles of use and especially in nulligravid women. The use of CC should be restricted to 6 cycles. Moreover, malignant melanoma and thyroid cancer risk was found to be higher among CC treated women in almost all studies. Further works should be conducted especially in animal models to assess its risk features.

show abstract

A Clomiphene Citrate and Letrozol Varsus Tamoxifen and Letrozole as an Infertility Treatment in Women with Polycystic Ovary Syndrome

Cited by 2 publications

References 25 publications

Combined Letrozole and Clomiphene versus Letrozole with low dose gonadotropin protocol for ovulation induction in infertile clomiphene-resistant women with polycystic ovary syndrome: Comparative study

Combined Letrozole and Clomiphene versus Letrozole with low dose gonadotropin protocol for ovulation induction in infertile clomiphene-resistant women with polycystic ovary syndrome: Comparative study

Safety of clomiphene citrate: a literature review

Contact Info

Product

Resources

About